Cargando…

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

The biology of breast cancer response to neoadjuvant therapy is underrepresented in the literature and provides a window-of-opportunity to explore the genomic and microenvironment modulation of tumours exposed to therapy. Here, we characterised the mutational, gene expression, pathway enrichment and...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Mattos-Arruda, Leticia, Cortes, Javier, Blanco-Heredia, Juan, Tiezzi, Daniel G., Villacampa, Guillermo, Gonçalves-Ribeiro, Samuel, Paré, Laia, Souza, Carla Anjos, Ortega, Vanesa, Sammut, Stephen-John, Cusco, Pol, Fasani, Roberta, Chin, Suet-Feung, Perez-Garcia, Jose, Dienstmann, Rodrigo, Nuciforo, Paolo, Villagrasa, Patricia, Rubio, Isabel T., Prat, Aleix, Caldas, Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185105/ https://www.ncbi.nlm.nih.gov/pubmed/34099718 http://dx.doi.org/10.1038/s41523-021-00282-0

Ejemplares similares

Intersect-then-combine approach: improving the performance of somatic variant calling in whole exome sequencing data using multiple aligners and callers
por: Callari, Maurizio, et al.
Publicado: (2017)

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
por: Pascual, Tomás, et al.
Publicado: (2021)

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
por: Griguolo, G., et al.
Publicado: (2021)

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
por: Brasó-Maristany, Fara, et al.
Publicado: (2020)

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Schettini, Francesco, et al.
Publicado: (2021)

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial
por: Guarneri, Valentina, et al.
Publicado: (2022)

Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Schettini, Francesco, et al.
Publicado: (2023)

Liquid biopsy for HER2-positive breast cancer brain metastasis: the role of the cerebrospinal fluid
por: De Mattos-Arruda, Leticia
Publicado: (2017)

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer
por: Pascual, Tomás, et al.
Publicado: (2021)

Dissecting the biological heterogeneity of HER2-positive breast cancer
por: Schettini, Francesco, et al.
Publicado: (2021)

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
por: Adamo, Barbara, et al.
Publicado: (2019)

Intrinsic molecular subtypes of HER2+ breast cancer
por: Prat, Aleix, et al.
Publicado: (2017)

Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
por: Prat, Aleix, et al.
Publicado: (2022)

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2021)

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2019)

The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver
por: Hruschka, Natascha, et al.
Publicado: (2020)

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study
por: Pernas, Sonia, et al.
Publicado: (2021)

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
por: Pascual, Tomás, et al.
Publicado: (2019)

Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials
por: Fernandez-Martinez, Aranzazu, et al.
Publicado: (2023)

Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer
por: Rodriguez-Freixinos, Victor, et al.
Publicado: (2019)

Computational approach to discriminate human and mouse sequences in patient-derived tumour xenografts
por: Callari, Maurizio, et al.
Publicado: (2018)

ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
por: Griguolo, Gaia, et al.
Publicado: (2020)

Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer
por: Serna, G., et al.
Publicado: (2020)

Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer
por: Serna, Garazi, et al.
Publicado: (2019)

Calling Sample Mix-Ups in Cancer Population Studies
por: Lynch, Andy G., et al.
Publicado: (2012)

MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients
por: De Mattos-Arruda, Leticia, et al.
Publicado: (2015)

PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution
por: Pernas, Sonia, et al.
Publicado: (2019)

Prognostic Value of MammaPrint(®) in Invasive Lobular Breast Cancer
por: Beumer, Inès J., et al.
Publicado: (2016)

Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution
por: Pernas, Sonia, et al.
Publicado: (2019)

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
por: Gavilá, Joaquín, et al.
Publicado: (2019)

Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA
por: Gao, Meiling, et al.
Publicado: (2019)

High-resolution array CGH clarifies events occurring on 8p in carcinogenesis
por: Cooke, Susanna L, et al.
Publicado: (2008)

Quantification of HER family receptors in breast cancer
por: Nuciforo, Paolo, et al.
Publicado: (2015)

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
por: Caswell-Jin, Jennifer L., et al.
Publicado: (2019)

Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
por: Caswell-Jin, Jennifer L., et al.
Publicado: (2019)

Genome-driven integrated classification of breast cancer validated in over 7,500 samples
por: Ali, H Raza, et al.
Publicado: (2014)

The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer
por: De Mattos-Arruda, Leticia, et al.
Publicado: (2019)

Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
por: Díaz-Gil, Laura, et al.
Publicado: (2021)

TOX3 Mutations in Breast Cancer
por: Jones, James Owain, et al.
Publicado: (2013)

Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancers
por: Chin, Suet-Feung, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cqsh84tne69824tuc6ub989g7v